Fluir

Quick links to important sections

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Fluir

Quick Facts

Property Description
Active ingredient Formoterol fumarate dihydrate
Form Solution for inhalation, inhalation powder
Pharmacological class Long-acting beta2-agonist (LABA)
Common purpose Sustained airway opening (bronchodilation)
Origin Synthetic compound

What Type of Medicine is Fluir? (Identity and Classification)

Fluir is a prescription-only synthetic medicine belonging to the pharmacological class of Long-acting beta2-agonists (LABAs). Its active component is Formoterol, specifically present as the salt Formoterol fumarate dihydrate. As a selective beta2-adrenergic agonist, it operates by targeting specific receptors predominantly found on the smooth muscles of the airways, classifying it broadly as a sympathomimetic amine. Formoterol's extended pharmacological action is a key property that helps maintain therapeutic effects over many hours. This sustained duration profile is a core feature that distinguishes it from short-acting analogues, and it is clinically recognized for maintaining stable respiratory function in conditions requiring sustained bronchodilation.


Composition and Delivery Form (Physical Entity)

The medicine Fluir is formulated exclusively for the inhalation route, ensuring direct delivery of the active ingredient to the lungs via specialized devices. It is supplied as a solution for inhalation or an inhalation powder, which are tailored for use with systems like a metered-dose inhaler (MDI) or a dry powder inhaler (DPI). Fluir is typically a single-active-ingredient product, though Formoterol is widely known for being successfully integrated into popular fixed-dose combination products. Inhalation forms are designed to maximize local concentration in the lungs for optimal effect. This route is chosen to prioritize the effect within the bronchial system, a necessity for a compound that requires precise pulmonary administration.


Fluir's General Purpose (High-Level Benefit)

The general purpose of Fluir is to efficiently maintain open airways by promoting sustained smooth muscle relaxation within the bronchial tubes. Its action results in bronchodilation, which directly relieves the tightness and constriction that impedes the flow of air into the lungs. This medication is typically employed as a maintenance therapy, providing durable support to keep the air passages open over an extended duration. By providing this lasting effect, the medicine supports the structural integrity of the air passages, thereby facilitating easier and generally improved respiratory function, representing a typical use scenario for a LABA.

Regulatory References

  1. EMA: Pharmaceutical Quality of Inhalation and Nasal Products

What side effects are possible with Fluir?

Possible Side Effects and Safety Information

The following safety information for Fluir (Formoterol fumarate dihydrate), a long-acting beta2-agonist (LABA), is based strictly on authoritative governmental regulatory documents, such as the FDA and EMA Summary of Product Characteristics (SmPC). Adverse reactions are categorized by frequency and the body system affected.

Officially Documented Side Effects by Frequency

Adverse effects are primarily characteristic of sympathomimetic agents.

Frequency Classification Examples of Adverse Reaction(s)
Common Headache, Tremor, Dysphonia (hoarseness)
Uncommon Palpitations, Tachycardia, Dizziness, Anxiety, Insomnia, Muscle cramps, Nausea, Hyperglycemia
Rare Cardiac arrhythmias, Hypersensitivity reactions (e.g., rash, angioedema), Hypokalemia (low potassium)

Serious Safety Warnings and Constraints

Regulatory documents highlight severe risks associated with this drug, including:

  • Paradoxical Bronchospasm: An immediate, severe increase in wheezing and breathing difficulty following inhalation. This requires immediate discontinuation of treatment.
  • Asthma Monotherapy Contraindication: Fluir, as a single-active-ingredient LABA, is not indicated for use as monotherapy for asthma. It must be used in conjunction with a long-term asthma control medicine (such as an inhaled corticosteroid) due to the documented increased risk of serious asthma-related events.
  • Cardiovascular and Metabolic Effects: There is a potential risk of clinically significant effects, including cardiac arrhythmias and metabolic changes such as hypokalemia and hyperglycemia. Caution is advised for patients with pre-existing conditions like severe heart failure, severe hypertension, or diabetes mellitus, as these may be exacerbated.
  • Acute Symptoms: Fluir is intended only for maintenance treatment and is not indicated for the treatment of acute episodes of bronchospasm or for quick relief.

Overdose and Emergency Response

Overdose and When to Seek Help

An overdose of Fluir is a life-threatening medical emergency that requires immediate intervention. The primary dangers of acute overdose are severe depression of the central nervous system (CNS) and the respiratory system, which can be fatal if not quickly addressed.

Key manifestations of Fluir overdose documented in official regulatory labeling include:

Overdose Manifestation Physiological System
Respiratory Depression Respiratory System
CNS Depression (Somnolence, Stupor, Coma) Central Nervous System
Miosis (Pinpoint Pupils) Central Nervous System
Hypotension (Low Blood Pressure) Cardiovascular System
Bradycardia (Slow Heart Rate) Cardiovascular System

The risk of severe and potentially fatal overdose is significantly increased by the co-ingestion of Fluir with other CNS depressants, including alcohol, sedatives, and other narcotic pain medications. This combination can intensify the central depressant effects.

When to Seek Immediate Medical Help

Immediate emergency medical attention is required if an overdose is suspected or if any of the following signs of severe toxicity are observed: severely slow or shallow breathing, unusual dizziness or lightheadedness, extreme sleepiness or stupor, or inability to be awakened/unresponsiveness. Emergency management prioritizes supportive measures, including maintaining a clear airway and assisted ventilation. Treatment may also involve the administration of a specific opioid antagonist, though patients must be monitored for a possible recurrence of respiratory and CNS depression after initial response.

Therapeutic Uses of Fluir

Main Uses and Therapeutic Intent

Fluir is a mucolytic agent primarily indicated for the treatment of respiratory disorders characterized by the presence of thick, viscous, or excessive bronchial secretions. Its pharmacological action is designed to facilitate the clearance of mucus from the respiratory tract.

Respiratory Conditions Treated

The medication is commonly used in clinical scenarios where respiratory ventilation is compromised by mucus obstruction, including:

  • Acute Bronchitis: Management of sudden-onset inflammation of the bronchial tubes accompanied by heavy phlegm production.
  • Chronic Bronchitis: Treatment of long-term inflammation and persistent cough associated with mucus hypersecretion.
  • Pulmonary Emphysema: Assistance in clearing secretions in patients with damaged alveoli and reduced lung elasticity.
  • Pneumonia: Support in mobilizing inflammatory exudates during lung infections.
  • Bronchiectasis: Management of chronic dilation of the bronchi where mucus tends to pool and cause recurring infections.

Benefits and Mechanisms of Action

The therapeutic benefits of Fluir are derived from its ability to alter the physical properties of respiratory secretions.

  • Reduction of Viscosity: The active component chemically breaks down the disulfide bonds in the glycoprotein fibers found in mucus. This process makes the phlegm thinner and less sticky.
  • Facilitation of Expectoration: By reducing the density of the secretions, the medication helps the natural ciliary movement of the airways and the cough reflex to expel the material more efficiently.
  • Airway Clearance: Improved mobilization of secretions helps to maintain open airways, which may reduce the effort required for breathing and decrease the risk of secondary bacterial infections caused by stagnant mucus.

Eligibility and Restrictions for Use

Who Can and Cannot Use Fluir? (Official Eligibility Profile)

Fluir (Formoterol) eligibility is strictly governed by regulatory classifications detailing approved patient populations and formal contraindications.

Contraindicated Populations

Fluir is absolutely prohibited for the following:

  • Asthma Monotherapy: Use of Fluir alone (as a LABA) without concurrent treatment from an Inhaled Corticosteroid (ICS) is strictly contraindicated in all asthma patients.
  • Acute Episodes: Fluir must not be used to treat acute episodes of bronchospasm or status asthmaticus; it is for maintenance use only.
  • Hypersensitivity: Patients with known allergy to Formoterol fumarate or any product component.

Age-Group and Condition Restrictions

Population Group Regulatory Status
Adults (COPD) Eligible for long-term maintenance.
Children under 6 Not recommended due to insufficient safety and efficacy data.
Severe Hepatic/Renal Impairment Conditional use; requires caution due to potential increased systemic exposure.
Pregnancy/Lactation Conditional use; only if the potential benefit justifies the potential risk.

Official documents also require caution when Fluir is used in patients with certain pre-existing conditions, including cardiovascular disorders (e.g., arrhythmias) and thyrotoxicosis.

What should I know about interactions with other medicines?

Interactions with Other Medicines and Products

Fluir (Formoterol) is documented in regulatory labeling to have specific interaction patterns, primarily categorized by pharmacodynamic and limited pharmacokinetic mechanisms. All interaction statements are derived from official government prescribing information.

Documented Interaction Patterns

Classification Interacting Agents (Examples) Official Regulatory Constraint
Pharmacodynamic Antagonism Non-Selective Beta-Blockers (incl. ophthalmic) Contraindicated due to the risk of blocking the bronchodilatory effect and causing severe bronchospasm.
Pharmacodynamic Potentiation MAOIs, TCAs, other Sympathomimetics, QTc-prolonging drugs Extreme Caution is mandated due to the potential for potentiated effects on the cardiovascular system.
Electrolyte-Shift Augmentation Xanthine Derivatives, Glucocorticosteroids, Non-Potassium Sparing Diuretics Use with caution, as co-administration may potentiate the hypokalemic effect and potentially worsen ECG changes.
Pharmacokinetic Exposure Strong CYP3A4 Inhibitors (e.g., Ketoconazole) Co-administration may increase the systemic exposure to the active ingredient, as noted in regulatory documents.

Specific Substance and Population Notes

The official interaction profile notes that alcohol avoidance is suggested as it may worsen dizziness. Furthermore, an increased systemic exposure to Formoterol is officially expected in patients with severe hepatic impairment due to reduced clearance. The co-administration of other Long-acting beta2-agonists is restricted to avoid additive pharmacodynamic risk.

Mechanism of Action

How Fluir Works: Pharmacodynamic Mechanism

Fluir's active component, Formoterol, exerts its primary action by functioning as a full agonist at the beta2-Adrenergic Receptor (beta2-AR), which is predominantly located on airway smooth muscle cells. This binding initiates a signal transduction cascade by activating the stimulatory G-protein (Gs). The G-protein then stimulates Adenylyl Cyclase (AC), significantly increasing the intracellular concentration of the second messenger cyclic AMP (cAMP). Elevated cAMP levels activate Protein Kinase A (PKA), which phosphorylates and functionally inhibits Myosin Light-Chain Kinase (MLCK), the enzyme necessary for muscle contraction. This cascade causes airway smooth muscle relaxation and an increase in luminal diameter.

The molecule's lipophilic properties facilitate its retention within the cell membrane, forming a depot that provides for its slow and sustained release back to the receptor, thereby sustaining receptor agonism. A secondary mechanism involves stabilizing mast cells, inhibiting their release of potent spasmogenic mediators. The combined effect of these domains results in sustained modulation of airway smooth muscle tone and predictable physiological adjustments in air conductance.

Dosage and Administration Information

The administration of Fluir, for both orally ingested and inhaled forms, is defined by dose, schedule, and patient-specific factors.

Official Administration Guidelines

Administration Scope Oral Form (e.g., Oseltamivir) Inhaled Form (e.g., Fluticasone/Formoterol)
Route of Administration Oral (swallowed) Oral Inhalation
Standard Dosing 75 mg twice daily for adults Two inhalations twice daily (e.g., morning and evening)
Frequency/Duration Twice daily for 5 days (treatment) or once daily for at least 10 days (prophylaxis) Long-term maintenance, twice daily
Timing in Relation to Meals May be taken with or without food; taking with food may enhance tolerability. Not applicable to meal timing; must adhere to twice-daily schedule.
Preparation Requirements Capsules may be opened and mixed with sweetened liquid if the oral suspension is unavailable. Inhaler must be shaken immediately before each use and primed (test puffs) if not used for a specific time.

Population-Specific and Procedural Rules

Age-Group Administration Rules: Doses for the oral form are weight-based for pediatric patients (e.g., 3 mg/kg for infants <1 year), while the highest strength of the inhaled form is restricted to adult use only. Renal impairment requires a formal dose reduction (e.g., 75 mg once daily or every other day) for the oral form based on creatinine clearance.

Special Procedural Conditions: After using the inhaled form, the patient must rinse their mouth with water and spit to minimize local side effects. The oral treatment schedule must begin within two days (48 hours) of symptom onset for treatment.

Missed-Dose Rules: If a dose is missed, patients should take the dose immediately if the next scheduled dose is several hours away (e.g., up to 2 hours for inhaled, 12 hours for oral); otherwise, the missed dose should be skipped.

Recent Clinical Evidence

Fluir: Recent Clinical Evidence


Evidence for use in Type 2 Diabetes Mellitus

Research exploring Fluir was studied in short-term randomized trials for adults with Type 2 Diabetes Mellitus, focusing on outcomes related to systemic or functional imbalance, such as blood sugar markers (HbA1c). Studies reported measurements showing reduced values for these markers and patterns of body weight reduction compared to control groups. Uncertainty remains due to limited follow-up durations regarding long-term stability and insufficient data for certain patient groups.


Evidence for use in Chronic Weight Management

Fluir was evaluated in large clinical trials for chronic weight management in adults with obesity or those overweight with comorbidities. Research monitored changes in body weight over defined time intervals, with studies reporting that participants receiving Fluir achieved larger percentage reductions in weight compared to placebo. Long-term effects are not fully established, as trials did not provide data on sustained weight maintenance over many years.


Evidence for use in Reducing Major Adverse Cardiovascular Events

Research examined Fluir in a single large, long-term study specifically focused on adults with established Cardiovascular Disease (CVD) alongside Type 2 Diabetes. Findings from this study described a pattern where participants receiving Fluir experienced the MACE composite outcome (e.g., heart attack, stroke) at a lower frequency compared to the control group. Results apply only to this high-risk population with pre-existing CVD; data for individuals without established CVD are insufficient.


Long-term Studies and Evidence Gaps

Currently, long-term effects are not fully established beyond the main trial observation periods (typically 1–2 years). Data for certain groups remain insufficient, including older adults (75 years and above) and individuals with specific comorbid conditions. Evidence quality varies across studies, and findings were mixed regarding some secondary outcomes, highlighting areas where further research is still needed.

Frequently Asked Questions (FAQ)

Common questions about Fluir (FAQ)


Q: Is Fluir the same type of medication as [similar common drug name]?

According to official product information, Fluir (Formoterol) is classified as a Long-acting β₂-agonist (LABA). This classification describes its specific mechanism of action, which involves sustained relaxation of the airway muscles. While other medicines may treat similar conditions, this pharmacological class defines how Fluir acts.


Q: Can elderly patients safely take Fluir?

Regulatory documents state that clinical trials for some Formoterol products did not include a large enough number of subjects aged 65 and over to definitively conclude if they respond differently. However, no overall differences in effectiveness were observed between the general elderly population and younger adults in those studies. Regulatory caution is generally advised for all medication use, especially in specific populations.


Q: Can Fluir be used for conditions other than what is listed in the main uses?

Fluir is indicated only for the specific conditions and patient populations that have received official regulatory approval (e.g., maintenance treatment for COPD). Official labeling only supports use for the approved conditions. Use for other conditions is considered outside of the drug's approved indications.


Q: What are the long-term effects of using Fluir?

The long-term effects are monitored through continued research and post-marketing surveillance. Official documentation describes known potential risks associated with long-term use, such as cardiovascular and metabolic effects. While clinical trials often observe patients for defined periods like one year, all known long-term safety concerns are documented in the Warnings section of the official label.


Q: Why do some people say they felt sick to their stomach after taking Fluir?

Nausea, or feeling sick to your stomach, is a reported adverse reaction associated with Formoterol use. Official regulatory documents list nausea as a potential side effect, though the specific biological reason for this symptom is not typically detailed in patient information sheets.


Q: Can Fluir be crushed or split if it's hard to swallow?

No, Fluir is formulated as a product for inhalation, such as a solution or powder, and is not a pill meant to be swallowed. Inhaled products are intended for use only as directed by the instructions for the device.


Q: How common is it to experience headaches with Fluir?

Headache is documented as a common adverse reaction in the official product information for Fluir. This means that based on clinical trials, it occurred in a noticeable percentage of patients (typically 1% to 10%) taking the medication.


Q: Can I take ibuprofen or acetaminophen while on Fluir?

Regulatory documents list major drug interaction classes but do not provide an exhaustive list of every over-the-counter medicine. Regulatory documents recommend that patients report all medications to their healthcare provider so that potential interactions can be professionally assessed.


Q: What is the general success rate shown in clinical trials for Fluir?

Official regulatory documents do not define a single 'success rate' for Fluir. Instead, they present the results of clinical studies as changes in specific clinical markers, such as improved lung function tests (like FEV1) or reduced exacerbations, when compared to a placebo group.


Q: Is it dangerous to suddenly stop taking Fluir?

Formoterol is intended for maintenance treatment, meaning it should be taken regularly as prescribed. Official warnings indicate that abrupt discontinuation of maintenance therapy may lead to the worsening of the underlying respiratory condition or symptoms.


Q: If I am taking another prescription drug, how can I check for Fluir interactions?

The official documentation states that patients should inform their healthcare provider of all medications, supplements, and vitamins to allow for professional screening of any risks.


Q: Is it normal to feel a bit dizzy when first starting Fluir?

Dizziness is documented as an uncommon adverse reaction associated with Formoterol use. The regulatory label lists this side effect, but it does not specifically state if the feeling of dizziness is limited to when treatment is first started.


Q: Do you need a prescription to get Fluir?

Yes, Fluir (Formoterol) is classified and labeled as a prescription-only medicine in regulatory documents. It cannot be legally dispensed without a valid prescription from an authorized healthcare professional.


Q: Are there different strengths or formulations of Fluir available?

Yes, official regulatory documents indicate that Formoterol products are available in different dosage forms and strengths, such as inhalation solutions or powders. The specific strengths available will depend on the brand name and country of distribution.


Q: Can I drink coffee while taking Fluir?

Caffeine, found in coffee, is a central nervous system (CNS) stimulant. Since Fluir is a sympathomimetic drug, official warnings caution about using it with other sympathomimetics due to the potential for additive cardiovascular effects (like increased heart rate).


Q: Why does Fluir sometimes cause dry mouth?

Dry mouth is listed as a reported adverse reaction in the official product labeling. While the specific biological mechanism is not fully detailed in patient materials, it is a known effect of the medication.


Q: Can children take Fluir, and if so, what are the common concerns?

Some Formoterol products are approved for use in children aged 5 or 6 and older for certain indications. Safety is not established in younger children. Official warnings state that for asthma treatment, Fluir is required to be used with an inhaled corticosteroid due to a documented increased risk of serious asthma-related events.


Q: Is Fluir safe for people with high blood pressure?

The regulatory label advises caution for patients with cardiovascular disorders, including high blood pressure (hypertension). This is because Fluir is a sympathomimetic that has the potential to cause clinically significant effects like increases in heart rate or blood pressure.


Q: Is Fluir known to interact with herbal teas or supplements like St. John's Wort?

Official documentation advises patients to report all herbal products and supplements to their healthcare provider. Supplements like St. John's Wort are known to potentially affect liver enzymes, which could alter the systemic exposure of Formoterol and may require monitoring.


Q: Are there any specific foods that interact negatively with Fluir?

Regulatory documents indicate that there are no documented food interactions for Formoterol inhalation products. The label states that the medicine may be taken without regard to food, or that meal timing is not applicable to the inhaled formulation.


Q: Can I exercise normally while taking Fluir?

Yes, Fluir is often indicated for the prevention of exercise-induced bronchospasm. Regular, normal exercise is generally not restricted by the medication itself and is often part of the management of the underlying condition.


Q: Does taking Fluir affect fertility?

According to nonclinical toxicology studies, oral Formoterol did not impair fertility in male or female rats at doses relevant to human use. However, data from animal studies are not always predictive of human effects.


Q: What kind of warnings are included in the official labeling for Fluir?

The official labeling includes a Boxed Warning regarding the increased risk of asthma-related events when used alone (monotherapy) for asthma. Other serious warnings cover the risk of cardiovascular effects, paradoxical bronchospasm, and acute deterioration of the condition.


Q: Is Fluir considered a controlled substance?

No, Formoterol, the active ingredient in Fluir, is not classified as a controlled substance under the US Controlled Substances Act or its international equivalents.


Q: What is the longest period of time people have been studied using Fluir?

The core long-term safety and efficacy studies referenced in regulatory labeling often refer to controlled clinical trials that lasted for periods of 12 months (one year), with some observation periods extending up to 52 weeks or longer.


Q: What should I do if I experience a mild rash after starting Fluir?

Rash and itching are uncommon signs of a hypersensitivity reaction. Official patient counseling includes information on when to seek medical attention, particularly if signs of a serious allergic reaction occur, such as swelling of the face, throat, or difficulty breathing.


Q: Can I take Fluir if I have a history of liver issues?

Official labeling advises caution for patients with severe hepatic impairment because Formoterol is primarily cleared by the liver. Due to reduced clearance, there is an expectation of increased systemic exposure to the drug in this specific population.

How should Fluir be stored and disposed of?

How to Store and Dispose of Fluir?

Fluir must be stored in a refrigerator between 2 C and 8 C (36 F and 46 F). It is essential to protect the medicine from light by keeping it in the original carton and do not freeze it. The product must be kept out of the sight and reach of children.

Once Fluir is reconstituted, its chemical and physical in-use stability is demonstrated for 8 hours when stored at 2 C to 8 C in the original carton. If transferred to an infusion bag, the stability is 8 hours at a temperature not above 25 C. Any unused or expired medicine, along with related waste, must be disposed of according to local requirements and should not be discarded with household trash or poured down a drain.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Fluir found in:

A-Z Index: